Holen Sie sich die Stockscreener-App
1.03
3.74%
-0.04
Handel nachbörslich:
1.02
-0.01
-0.97%
Schlusskurs vom Vortag:
$1.07
Offen:
$1.07
24-Stunden-Volumen:
1.39M
Relative Volume:
1.11
Marktkapitalisierung:
$194.60M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-0.6319
EPS:
-1.63
Netto-Cashflow:
$-193.47M
1W Leistung:
-24.82%
1M Leistung:
-26.95%
6M Leistung:
-41.31%
1J Leistung:
+113.91%
1-Tages-Spanne:
$1.02
$1.09
1-Wochen-Bereich:
$1.02
$1.375
52-Wochen-Spanne:
$0.4227
$1.928
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NKTR | 1.03 | 194.60M | 90.12M | -276.06M | -193.47M | -1.63 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Nektar presents preclinical data on NKTR-422 at ACR conference - TipRanks
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - Kilgore News Herald
Eventide Asset Management's Strategic Acquisition of Nektar Ther - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Nektar Therapeutics - GuruFocus.com
Multiple Catalysts Ahead For Nektar Therapeutics (NASDAQ:NKTR) - Seeking Alpha
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
Nektar Therapeutics to sell Alabama facility to Ampersand - MSN
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC - Targeted Oncology
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Canada Finance
Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Nektar Therapeutics progresses with key clinical studies By Investing.com - Investing.com UK
Nektar Therapeutics (NKTR) Quarterly 10-Q Report - Quartz
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Nektar reports NKTR-255 boosts lymphocyte recovery By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook - Yahoo Finance
Nektar: Q3 Earnings Snapshot - The Washington Post
Nektar Therapeutics Reports Stable Q3 Earnings for 2024 - TipRanks
Nektar Therapeutics Q3 2024 Earnings: Revenue Surpasses Estimate - GuruFocus.com
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c - StreetInsider.com
Nektar Therapeutics Narrows Losses, Sells Manufacturing Facility for $90M in Q3 | NKTR Stock News - StockTitan
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia - MSN
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more - MM+M Online
Nektar reports NKTR-255 boosts lymphocyte recovery - Investing.com
Nektar Therapeutics (NKTR) and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 - StreetInsider.com
Nektar's NKTR-255 Shows Breakthrough Results in Cancer Treatment Study with MD Anderson | NKTR Stock News - StockTitan
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook By GuruFocus - Investing.com Canada
Nektar Therapeutics to Present at UBS and Piper Sandler Healthcare Conferences | NKTR Stock News - StockTitan
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale - Yahoo Finance
Ampersand’s Acquisition of a Nektar’s Manufacturing Facility and Reagent Supply Business - Global Legal Chronicle
Nektar sells its PEGylation reagent manufacturing business - The Pharma Letter
Nektar divests manufacturing site and reagent arm for $90M - Endpoints News
Nektar announces agreement to sell Alabama manufacturing facility and reagent supply business - MSN
NKTRNektar Therapeutics Latest Stock News & Market Updates - StockTitan
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga
Nektar pads wallet with $90M manufacturing plant sale to Ampersand - FiercePharma
Nektar divests Alabama facility to Ampersand for $90 million By Investing.com - Investing.com Canada
Nektar Therapeutics Sells Manufacturing Facility for $90M - TipRanks
Nektar divests Alabama facility to Ampersand for $90 million - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper Sandler - MarketBeat
Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama - StreetInsider.com
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama - StockTitan
Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight - StreetInsider.com
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics for $90 million. - Marketscreener.com
Nektar Therapeutics (NKTR) Stock Surges Amidst Mixed Financials - GuruFocus.com
Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Thursday - MarketBeat
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets - Longview News-Journal
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):